Biotech Stock Entrada Surges On $250 Million Muscular Dystrophy Deal With Vertex
Entrada Therapeutics (TRDA) inked a $250 million deal with Vertex Pharmaceuticals (VRTX) to develop a muscular dystrophy drug, and the biotech stock surged.
X
Under the terms of the deal, Vertex will pay Entrada $224 million in…